Monthly News Roundup - May 2025
AbbVie’s Emrelis Approved for Non-Small Cell Lung Cancer With High c-Met Protein Overexpression Emrelis (telisotuzumab vedotin) is a first-in-class, c-Met protein directed antibody-drug conjugate now approved for the treatment of adult...
AbbVie’s Emrelis Approved for Non-Small Cell Lung Cancer With High c-Met Protein Overexpression
Emrelis (telisotuzumab vedotin) is a first-in-class, c-Met protein directed antibody-drug conjugate now approved for the treatment of adult...
